

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 March 2003 (20.03.2003)


PCT

(10) International Publication Number
WO 03/022809 A2

- (51) International Patent Classification⁷: C07D 207/00
- (21) International Application Number: PCT/GB02/04206
- (22) International Filing Date:
13 September 2002 (13.09.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0122156.3 13 September 2001 (13.09.2001) GB
0130547.3 20 December 2001 (20.12.2001) GB
0130503.6 20 December 2001 (20.12.2001) GB
0130505.1 20 December 2001 (20.12.2001) GB
- (71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; 980
Great West Road, Brentford, Middlesex TW8 9GS (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): RAMI, Harshad,
Kantilal [GB/GB]; GlaxoSmithKline, New Frontiers Sci-
ence Park South, Third Avenue, Harlow, Essex CM19 5AW
(GB). THOMPSON, Mervyn [GB/GB]; GlaxoSmithK-
line, New Frontiers Science Park South, Third Avenue,
Harlow, Essex CM19 5AW (GB). WYMAN, Paul, Adrian
[GB/GB]; GlaxoSmithKline, New Frontiers Science Park
South, Third Avenue, Harlow, Essex CM19 5AW (GB).
- (74) Agent: GIDDINGS, Peter, John; GlaxoSmithKline,
Corporate Intellectual Property_CN925.1, 980 Great West
Road, Brentford, Middlesex TW8 9EP (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



(54) Title: NOVEL COMPOUNDS



(57) Abstract: Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R¹, R², P, P', n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

NOVEL COMPOUNDS

This invention relates to novel compounds, especially urea derivatives,
5 having pharmacological activity, processes for their preparation, to compositions containing them and to their use in medicine, especially in the treatment of various disorders.

Vanilloids are a class of natural and synthetic compounds that are characterised by the presence of a vanillyl (4-hydroxy 3-methoxybenzyl) group or a
10 functionally equivalent group. Vanilloid Receptor (VR-1), whose function is modulated by such compounds, has been widely studied and is extensively reviewed by Szallasi and Blumberg (The American Society for Pharmacology and Experimental Therapeutics, 1999, Vol. 51, No. 2.).


A wide variety of Vanilloid compounds of different structures are known
15 in the art, for example those disclosed in European Patent Application Numbers, EP 0 347 000 and EP 0 401 903, UK Patent Application Number GB 2226313 and International Patent Application, Publication Number WO 92/09285. Particularly notable examples of vanilloid compounds or vanilloid receptor modulators are capsaicin or trans 8-methyl-N-vanillyl-6-nonenamide which is
20 isolated from the pepper plant, capsazepine (*Tetrahedron*, **53**, 1997, 4791) and olvanil or - N-(4-hydroxy-3-methoxybenzyl)oleamide (*J. Med. Chem.*, **36**, 1993, 2595).

US Patent Numbers, US 3,424,760 and US 3,424,761 both describe a series of 3-Ureidopyrrolidines that are said to exhibit analgesic, central nervous
25 system, and psychopharmacologic activities. These patents specifically disclose the compounds 1-(1-phenyl-3-pyrrolidinyl)-3-phenyl urea and 1-(1-phenyl-3-pyrrolidinyl)-3-(4-methoxyphenyl)urea respectively.

International Patent Applications, Publication Numbers WO 02/08221, WO 02/16317, WO 02/16318 and WO 02/16319 each disclose certain vanilloid
30 receptor antagonists and their use in the treatment of diseases associated with the activity of the vanilloid receptor.

Co-pending International Patent Application Number PCT/EP02/04802 discloses a series of urea derivatives and their use in the treatment of diseases associated with the activity of the vanilloid receptor.

According to a first aspect of the present invention, there is provided a
 5 compound of formula (I),



(I)

or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:

- 10 P and P' are independently selected from aryl and heteroaryl;
 R¹ and R² are independently selected from -H, halo, alkyl, alkoxy, cycloalkyl, aralkyl, aralkoxy, cycloalkylalkyl, cycloalkylalkoxy, -CN, -NO₂, -OH, -OCF₃, -CF₃, -NR⁴R⁵, -S(O)ₘR⁶, -S(O)₂NR⁴R⁵, -OS(O)₂R⁶, -OS(O)₂CF₃, -O(CH₂)ₓNR⁴R⁵, -C(O)CF₃, -C(O)alkyl, -C(O)cycloalkyl, -C(O)aralkyl, -C(O)Ar, -C(O)(CH₂)ₓOR⁶, -
 15 C(O)(CH₂)ₓNR⁴R⁵, -C(O)alkoxy, -C(O)NR⁴R⁵, -(CH₂)ₓC(O)alkoxy, -(CH₂)ₓOC(O)R⁶, -(CH₂)ₓOR⁶, -(CH₂)ₓR⁴R⁵, -(CH₂)ₓC(O)NR⁴R⁵, -(CH₂)ₓN(R⁴)C(O)R⁶, -(CH₂)ₓS(O)₂NR⁴R⁵, -(CH₂)ₓN(R⁴)S(O)₂R⁶, -ZAr, -(CH₂)ₓS(O)₂R⁶, -(OCH₂)ₓS(O)₂R⁶, -N(R⁴)S(O)₂R⁶, -N(R⁴)C(O)R⁶, -(CH₂)ₓN(R⁴)S(O)₂R⁶, -(CH₂)ₓN(R⁴)C(O)R⁶ or -(CH₂)ₓC(O)alkyl;
 20 R⁴ and R⁵ may be the same or different and represent H or alkyl or R⁴ and R⁵ together with the atoms to which they are attached form a C₃-₆azacycloalkane, C₃-₆(2-oxo)azacycloalkane ring or C₅-₈ polymethylene chain optionally interrupted by heteroatoms such as O or -NR⁷.
 Z is O, S or NR⁷;
 25 R⁶ is alkyl or aryl;
 R⁷ is hydrogen, alkyl or aryl;
 m is 1 or 2;
 n is 0, 1, 2 or 3;

p and q are independently 0, 1, 2, 3 or 4;

r is 1, 2 or 3;

s is 0, 1 or 2; and

x is 0, 1, 2, 3, 4, 5 or 6;

5 with the proviso that said compound of formula (I) is not a compound selected from:

- 1-(1-phenyl-3-pyrrolidinyl)-3-phenyl urea;
- 1-(1-phenyl-3-pyrrolidinyl)-3-(4-methoxyphenyl)urea;
- N*-(4-Fluorophenyl)-*N'*-[*((R)*-1-((3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- 10 *N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*-(4-Fluorophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*-(4-Fluorophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- 15 *N*-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(4-Fluorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(4-Fluorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)]pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(1-Naphthyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- 20 *N*-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea;
- 25 *N*-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2,5-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(2,5-Dichlorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- 30 *N*-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;


N-(2,5-Dichlorophenyl)-*N'*-[*[(R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl]]urea;
N-(3-Chloro-2-methylphenyl)-*N'*-[*[(R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl]]urea; and
N-(2,3-Dichlorophenyl)-*N'*-[*[(R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl]]urea.

5

Suitably, P and P' are independently selected from phenyl and heteroaryl.

In a preferred aspect of the present invention there is provided a subset of compounds of formula (I), of formula (IA),

10



(IA)

15 or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:

P is phenyl, naphthyl, quinolinyl or isoquinolinyl;

P' is phenyl or pyridyl;

R¹ and R² are independently selected from -H, halo, alkyl, alkoxy, cycloalkyl, aralkyl, aralkoxy, cycloalkylalkyl, cycloalkylalkoxy, -CN, -NO₂, -OH, -OCF₃, -CF₃,
 20 -NR⁴R⁵, -S(O)_mR⁶, -S(O)₂NR⁴R⁵, -OS(O)₂R⁶, -OS(O)₂CF₃, -O(CH₂)_xNR⁴R⁵,
 -C(O)CF₃, -C(O)alkyl, -C(O)cycloalkyl, -C(O)aralkyl, -C(O)Ar, -C(O)(CH₂)_xOR⁶, -
 C(O)(CH₂)_xNR⁴R⁵, -C(O)alkoxy, -C(O)NR⁴R⁵, -(CH₂)_xC(O)alkoxy, -
 (CH₂)_xOC(O)R⁶, -(CH₂)_xOR⁶, -(CH₂)_xR⁴R⁵, -(CH₂)_xC(O)NR⁴R⁵, -
 (CH₂)_xN(R⁴)C(O)R⁶, -(CH₂)_xS(O)₂NR⁴R⁵, -(CH₂)_xN(R⁴)S(O)₂R⁶, -ZAr, -
 25 (CH₂)_xS(O)₂R⁶, -(OCH₂)_xS(O)₂R⁶, -N(R⁴)S(O)₂R⁶, -N(R⁴)C(O)R⁶, -
 (CH₂)_xN(R⁴)S(O)₂R⁶, -(CH₂)_xN(R⁴)C(O)R⁶ or -(CH₂)_xC(O)alkyl;

R⁴ and R⁵ may be the same or different and represent H or alkyl or R⁴ and R⁵ together with the atoms to which they are attached form a C₃₋₆azacycloalkane,

C₃₋₆(2-oxo)azacycloalkane ring or C₅₋₈ polymethylene chain optionally interrupted by heteroatoms such as O or -NR⁷.

Z is O, S or NR⁷;

R⁶ is alkyl or aryl;

5 R⁷ is hydrogen, alkyl or aryl;

m is 1 or 2;

n is 0, 1, 2 or 3;

p and q are independently 0, 1, 2, 3 or 4;

r is 1, 2 or 3;

10 s is 0, 1 or 2; and

x is 0, 1, 2, 3, 4, 5 or 6;

with the proviso that said compound of formula (IA) is not a compound selected from:

1-(1-phenyl-3-pyrrolidinyl)-3-phenyl urea;

15 1-(1-phenyl-3-pyrrolidinyl)-3-(4-methoxyphenyl)urea;

N-(4-Fluorophenyl)-N'-[(R)-1-((3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;

N-(2-Bromophenyl)-N'-[((R)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-N'-[((R)-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;

N-(4-Fluorophenyl)-N'-[((S)-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;

20 N-(2-Bromophenyl)-N'-[((S)-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;

N-(4-Fluorophenyl)-N'-[((S)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-N'-[((S)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(4-Fluorophenyl)-N'-[((R)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(4-Fluorophenyl)-N'-[((R)-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

25 N-(2-Bromophenyl)-N'-[((R)-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

N-(1-Naphthyl)-N'-[((R)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2,3-Dichlorophenyl)-N'-[((R)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-N'-[((S)-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-N'-[((R)-1-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)]urea;

30 N-(2-Bromophenyl)-N'-[((R)-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-N'-[((R)-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea;

N-(3-Chloro-2-methylphenyl)-N'-[((R)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2,3-Dichlorophenyl)-N'-[((R)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;


- N -(2,5-Dichlorophenyl)- N' -[$((R)$ -1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
 N -(2,3-Dichlorophenyl)- N' -[$((R)$ -1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
 N -(2,5-Dichlorophenyl)- N' -[$((R)$ -1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
 N -(3-Chloro-2-methylphenyl)- N' -[$((R)$ -1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
5 N -(3-Chloro-2-methylphenyl)- N' -[$((R)$ -1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
 N -(2,3-Dichlorophenyl)- N' -[$((R)$ -1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
 N -(2,5-Dichlorophenyl)- N' -[$((R)$ -1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
 N -(3-Chloro-2-methylphenyl)- N' -[$((R)$ -1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea; and
10 N -(2,3-Dichlorophenyl)- N' -[$((R)$ -1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea.

Suitably, P is phenyl, quinolinyl or isoquinolinyl. More suitably P is phenyl, 5-quinolinyl, 7-quinolinyl or 5-isoquinolinyl. Preferably, P is phenyl or 5-isoquinolinyl.

- 15 Suitably, P' is phenyl. Suitably, P' is pyridyl.
Suitably, R^1 is halo, $-CF_3$ or alkyl. Preferably, R^1 is fluoro, chloro, bromo, $-CF_3$, methyl or *tert*-butyl.
When p is 2 or 3 the groups R^1 may be the same or different.
Suitably, p is 1 or 2. Preferably, p is 1.
20 Suitably, m is 1.
Suitably, n is 0 or 1. Preferably, n is 0.
Suitably, R^2 is halo, alkyl, alkoxy, $-CN$ or $-CF_3$. Preferably, R^2 is fluoro, chloro, bromo, methyl, OMe or CF_3 .
Suitably, q is 1 or 2. Preferably, q is 1.
25 Suitably, x is 1, 2 or 3.
When q is 2 or 3 the groups R^2 may be the same or different.
When q is 2, particularly preferred examples of R^2 are 3,4-difluoro, 3-fluoro-4-methyl, 3-methyl-4-fluoro, 3-chloro-5-trifluoromethyl, 3-cyano-5-trifluoromethyl and 3-cyano-6-trifluoromethyl.
30 Suitably, r and s have values such that they define a 4 - 7 membered ring.
Preferably, r and s have values such that they define a 5 or 6 membered ring.
Most preferably r and s have values such that they define a 5 membered ring.

According to a further preferred aspect of the present invention, there is provided a subset of compounds of formula (I), of formula (IB),

5



or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:

P is phenyl, naphthyl, quinoliny or isoquinoliny;

- 10 R¹ and R² are independently selected from -H, halo, alkyl, alkoxy, cycloalkyl, aralkyl, aralkoxy, cycloalkylalkyl, cycloalkylalkoxy, -CN, -NO₂, -OH, -OCF₃, -CF₃, -NR⁴R⁵, -S(O)_mR⁶, -S(O)₂NR⁴R⁵, -OS(O)₂R⁶, -OS(O)₂CF₃, -O(CH₂)_xNR⁴R⁵, -C(O)CF₃, -C(O)alkyl, -C(O)cycloalkyl, -C(O)aralkyl, -C(O)Ar, -C(O)(CH₂)_xOR⁶, -C(O)(CH₂)_xNR⁴R⁵, -C(O)alkoxy, -C(O)NR⁴R⁵, -(CH₂)_xC(O)alkoxy, -
- 15 (CH₂)_xOC(O)R⁶, -(CH₂)_xOR⁶, -(CH₂)_xR⁴R⁵, -(CH₂)_xC(O)NR⁴R⁵, -(CH₂)_xN(R⁴)C(O)R⁶, -(CH₂)_xS(O)₂NR⁴R⁵, -(CH₂)_xN(R⁴)S(O)₂R⁶, -ZAr, -(CH₂)_xS(O)₂R⁶, -(OCH₂)_xS(O)₂R⁶, -N(R⁴)S(O)₂R⁶, -N(R⁴)C(O)R⁶, -(CH₂)_xN(R⁴)S(O)₂R⁶, -(CH₂)_xN(R⁴)C(O)R⁶ or -(CH₂)_xC(O)alkyl;

R⁴ and R⁵ may be the same or different and represent H or alkyl or R⁴ and R⁵

- 20 together with the atoms to which they are attached form a C₃₋₆azacycloalkane, C₃₋₆(2-oxo)azacycloalkane ring or C₅₋₈ polymethylene chain optionally interrupted by heteroatoms such as O or -NR⁷.

Z is O, S or NR⁷;

R⁶ is alkyl or aryl;

- 25 R⁷ is hydrogen, alkyl or aryl;

m is 1 or 2;

n is 0, 1, 2 or 3;

p and q are independently 0, 1, 2, 3 or 4;

r is 1, 2 or 3;
 s is 0, 1 or 2; and
 x is 0, 1, 2, 3, 4, 5 or 6.


Suitably, R^1 is halo, hydroxy, alkyl, alkoxy, $-CF_3$, $-NO_2$, $-CN$, $-OCF_3$,
 5 amino or mono- or dialkylamino. Preferably, R^1 is halo, $-CF_3$ or alkyl. More
 preferably, R^1 is bromo, chloro, fluoro, $-CF_3$, methyl or *tert*-butyl;

Suitably, R^1 is halo, hydroxy, alkyl, alkoxy, $-CF_3$, $-NO_2$, $-CN$, $-OCF_3$,
 amino or mono- or dialkylamino. Preferably, R^2 is halo, alkyl, alkoxy, $-CN$, or -
 CF_3 . Preferably, R^2 is bromo, chloro, fluoro, methyl, $-OMe$ or $-CF_3$;

10 Suitably, p and q are independently 0, 1 or 2; and
 Suitably, r and s are independently 1 or 2.
 Suitably, x is 1, 2 or 3.

Compounds of formula (IB) of particular interest according to the present
 invention are Example numbers 1-23, 28, 29, 34-39, 44-50 and 55-76 (presented
 15 in Table 1 below) or pharmaceutically acceptable salts or solvates thereof.

According to a further aspect of the present invention, there is provided a
 subset of compounds of formula (I), of formula (IC),



20

or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:

P is phenyl, naphthyl, quinolinyl or isoquinolinyl;

R^1 and R^2 are independently selected from halo, hydroxy, alkyl, alkoxy, $-CF_3$, -
 NO_2 , $-CN$, $-OCF_3$, amino or mono- or dialkylamino

25 n is 0, 1, 2 or 3;

p and q are independently 0, 1, 2, 3 or 4;

r is 1, 2 or 3; and

s is 0, 1 or 2;

with the proviso that said compound of formula (I) is not a compound selected from:

- 1-(1-phenyl-3-pyrrolidinyl)-3-phenyl urea;
- 1-(1-phenyl-3-pyrrolidinyl)-3-(4-methoxyphenyl)urea;
- 5 *N*-(4-Fluorophenyl)-*N'*-[(*R*)-1-((3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*-(2-Bromophenyl)-*N'*-[(*R*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[(*R*)-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*-(4-Fluorophenyl)-*N'*-[(*S*)-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*-(2-Bromophenyl)-*N'*-[(*S*)-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- 10 *N*-(4-Fluorophenyl)-*N'*-[(*S*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[(*S*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(4-Fluorophenyl)-*N'*-[(*R*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(4-Fluorophenyl)-*N'*-[(*R*)-1-(3-fluorophenyl)]pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[(*R*)-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- 15 *N*-(1-Naphthyl)-*N'*-[(*R*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2,3-Dichlorophenyl)-*N'*-[(*R*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[(*S*)-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[(*R*)-1-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2-Bromophenyl)-*N'*-[(*R*)-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- 20 *N*-(2-Bromophenyl)-*N'*-[(*R*)-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(3-Chloro-2-methylphenyl)-*N'*-[(*R*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2,3-Dichlorophenyl)-*N'*-[(*R*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2,5-Dichlorophenyl)-*N'*-[(*R*)-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*-(2,3-Dichlorophenyl)-*N'*-[(*R*)-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- 25 *N*-(2,5-Dichlorophenyl)-*N'*-[(*R*)-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(3-Chloro-2-methylphenyl)-*N'*-[(*R*)-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(3-Chloro-2-methylphenyl)-*N'*-[(*R*)-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(2,3-Dichlorophenyl)-*N'*-[(*R*)-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- N*-(2,5-Dichlorophenyl)-*N'*-[(*R*)-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- 30 *N*-(3-Chloro-2-methylphenyl)-*N'*-[(*R*)-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea; and
- N*-(2,3-Dichlorophenyl)-*N'*-[(*R*)-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea.

Suitably, P is phenyl, quinolinyl or isoquinolinyl.

Suitably, R¹ is alkyl. Preferably R¹ is methyl.

Suitably, R² is halo or alkyl. Suitably, R² is fluoro or methyl.

5 Suitably, p and q are independently 0, 1 or 2.

Suitably, r and s are independently 1 or 2.

Compounds of formula (IC) of particular interest according to the present invention are Example numbers 24-27, 30-33, 40-43 and 51-54 (illustrated in Table 1 below) or pharmaceutically acceptable salts or solvates thereof.

10 Certain of the carbon atoms of formula (I) are chiral carbon atoms, such as the carbon atom marked with an "*", and therefore compounds of formula (I) may exist as stereoisomers. The invention extends to all optical isomers such as stereoisomeric forms of the compounds of formula (I) including enantiomers and mixtures thereof, such as racemates. The different stereoisomeric forms may be
15 separated or resolved one from the other by conventional methods or any given isomer may be obtained by conventional stereospecific or asymmetric syntheses.

Preferred compounds of formula (I) have the C* carbon in the R-configuration.

Certain of the compounds herein can exist in various tautomeric forms
20 and it is to be understood that the invention encompasses all such tautomeric forms.

As indicated above, the compounds of formula (I) can form salts, especially pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts are those use conventionally in the art and include those
25 described in *J. Pharm. Sci.*, 1977, 66, 1-19, such as acid addition salts.

Suitable pharmaceutically acceptable salts include acid addition salts.

Suitable pharmaceutically acceptable acid addition salts include salts with inorganic acids such, for example, as hydrochloric acid, hydrobromic acid, orthophosphoric acid or sulphuric acid, or with organic acids such, for example
30 as methanesulphonic acid, toluenesulphonic acid, acetic acid, propionic acid, lactic acid, citric acid, fumaric acid, malic acid, succinic acid, salicylic acid, maleic acid, glycerophosphoric acid or acetylsalicylic acid.

The salts and/or solvates of the compounds of the formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the preparation of pharmaceutically acceptable salts and/or solvates of compounds of formula (I) or the compounds of the formula (I) themselves, and as such form
5 another aspect of the present invention.

The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and if crystalline, may be optionally hydrated or solvated. This invention includes in its scope stoichiometric hydrates as well as compounds containing variable amounts of water.

10 Suitable solvates include pharmaceutically acceptable solvates, such as hydrates.

Solvates include stoichiometric solvates and non-stoichiometric solvates.

As used herein the term "alkyl" as a group or part of a group refers to a straight or branched chain saturated aliphatic hydrocarbon radical containing 1 to
15 12 carbon atoms, suitably 1 to 6 carbon atoms. Such alkyl groups in particular include methyl ("Me"), ethyl ("Et"), n-propyl ("Prⁿ"), *iso*-propyl ("Prⁱ"), n-butyl ("Buⁿ"), *sec*-butyl ("Bu^s"), *tert*-butyl ("Bu^t"), pentyl and hexyl. Where appropriate, such alkyl groups may be substituted by one or more groups selected from halo (such as fluoro, chloro, bromo), -CN, -CF₃, -OH, -OCF₃, C₂₋₆ alkenyl, C₃₋₆ alkynyl, C₁₋₆ alkoxy, aryl and di-C₁₋₆ alkylamino.
20

As used herein, the term "alkoxy" as a group or part of a group refers to an alkyl ether radical, wherein the term "alkyl" is defined above. Such alkoxy groups in particular include methoxy, ethoxy, n-propoxy, *iso*-propoxy, n-butoxy, *iso*-butoxy, *sec*-butoxy and *tert*-butoxy. Where appropriate, such alkoxy groups
25 may be substituted by one or more groups selected from halo (such as fluoro, chloro, bromo), -CN, -CF₃, -OH, -OCF₃, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ alkynyl, aryl and di-C₁₋₆ alkylamino.

As used herein, the term "aryl" as a group or part of a group refers to a carbocyclic aromatic radical ("Ar"). Suitably such aryl groups are 5-6 membered
30 monocyclic groups or 8-10 membered fused bicyclic groups, especially phenyl ("Ph"), biphenyl and naphthyl, particularly naphthyl and phenyl.


As used herein, the term "heteroaryl" as a group or part of a group refers to a stable 5- 7-membered monocyclic or 7- to 10-membered bicyclic

heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4, suitably from 1 to 2, heteroatoms independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of suitable heteroaryl groups include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolyl, decahydroquinolyl, 2H, 6H-1,5,2-dithiazinyl, dihydrobenzofuranyl, furanyl, furazanyl, imidazolyl, 1H-indazolyl, indolyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, pyrimidinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydroisoquinolyl, tetrahydroquinolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl.

The term "halo" is used herein to describe, unless otherwise stated, a group selected from fluorine ("fluoro"), chlorine ("chloro"), bromine ("bromo") or iodine ("iodo").

The term "naphthyl" is used herein to denote, unless otherwise stated, both naphth-1-yl and naphth-2-yl groups.


The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises coupling a compound of formula (II):



(II)

in which R^1 , P and p are as defined in formula (I) with a compound of formula (III):

5



- 10 in which P' , R^2 , n, q, r and s are as defined in formula (I) and A and B contain appropriate functional groups which are capable of reacting together to form the urea moiety;
and thereafter, as necessary, carrying out one or more of the following reactions:
(i) converting one compound of formula (I) into another compound of formula (I);
15 (ii) removing any protecting group;
(iii) preparing a salt or a solvate of the compound so formed.

Suitable examples of appropriate A and B groups include:

- (a) A is $-N=C=O$ and B is NH_2 ; or A is NH_2 and B is $N=C=O$ or
(b) A is NH_2 and B is NH_2 together with an appropriate urea forming agent.
20 In process (a) the reaction is carried out in an inert solvent such as dichloromethane or acetonitrile.


In process (b) the urea forming agent can be carbonyl diimidazole or phosgene or triphosgene, and carried out in an inert organic solvent such as diethyl ether, tetrahydrofuran or dichloromethane at ambient or elevated
25 temperature in the presence of a base such as triethylamine or pyridine.

An alternative method of synthesis of the unsymmetrical urea compounds of formula (I) is from a diaryl carbonate, via the corresponding carbamate. Such a methodology is described by Freer et al. (Synthetic


Communications, 26(2), 331 - 349, 1996). It would be appreciated by those skilled in the art that such a methodology could be readily adapted for preparation of the compounds of formula (I).

It will be appreciated by those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above-mentioned procedures. Standard protection and deprotection techniques, such as those described in Greene T.W. 'Protective groups in organic synthesis', New York, Wiley (1981), can be used. For example, primary amines can be protected as phthalimide, benzyl, benzyloxycarbonyl or trityl derivatives. Carboxylic acid groups can be protected as esters. Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection of such groups is achieved using conventional procedures well known in the art.

A compound of formula (III) may be prepared by reaction of a compound of formula (IV):



wherein, P' is as defined in relation to formula (I) and R^{2'} is R² as defined above or a protected form thereof, L¹ is a leaving group and q is as defined above, with a compound of formula (V):



wherein B' is B as defined above or a protected form thereof and n, r and s are as defined above.

Suitably L¹ is a halogen, such as chlorine.

Suitably, the compound of formula (V) is in an activated form, for example an ionic form. Such activated forms are prepared using conventional coupling reaction methodology, as for example by reacting compounds (IV) and (V) in the presence of an alkali carbonate, such as potassium carbonate, in an aprotic solvent such as dimethylformamide using reaction conditions appropriate to the particular methodology chosen, for example at an elevated temperature, such as 100°C.

Compounds of formulae (IV) and (V) are commercially available, or are prepared by known procedures, such as those disclosed in: *Heterocycles*, 1984, 22(1), 117 and *J. Chem. Soc., Perkin 1*, 1988, 4, 921 for compounds of formula (IV) and *J. Med. Chem.*, 1992, 35(10), 1764 for compounds of formula (V), or by methods analogous to these disclosed methods.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

Compounds of formula (I) and their pharmaceutically acceptable salts have Vanilloid receptor antagonist (VR1) activity and are believed to be of potential use for the treatment or prophylaxis of certain disorders, or treatment of the pain associated with them, such as: pain, chronic pain, neuropathic pain, postoperative pain, postrheumatoid arthritic pain, osteoarthritic pain, back pain, visceral pain, cancer pain, algesia, neuralgia, dental pain, headache, migraine, neuropathies, carpal tunnel syndrome, diabetic neuropathy, HIV-related neuropathy, post-herpetic neuralgia, fibromyalgia, neuritis, sciatica, nerve injury, ischaemia, neurodegeneration, stroke, post stroke pain, multiple sclerosis, respiratory diseases, asthma, cough, COPD, broncho constriction, inflammatory disorders, oesophagitis, heart burn, Barrett's metaplasia, dysphagia, gastroesophageal reflux disorder (GERD), stomach and duodenal ulcers, functional dyspepsia, irritable bowel syndrome, inflammatory bowel disease, colitis, Crohn's disease, pelvic hypersensitivity, pelvic pain, menstrual pain, renal colic, urinary incontinence, cystitis, burns, itch, psoriasis, pruritis, emesis (hereinafter referred to as the "Disorders of the Invention").

Accordingly, the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use as an active

therapeutic substance, in particular in the treatment and/or prophylaxis of the Disorders of the Invention.

In particular, the invention provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment or
5 prophylaxis of pain.

The invention further provides a method for the treatment or prophylaxis of disorders in which antagonism of the Vanilloid (VR1) receptor is beneficial, in particular the Disorders of the Invention, in mammals including humans, which comprises administering to a mammal in need thereof a therapeutically effective
10 amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

The invention provides for the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prophylaxis of disorders in which an antagonist
15 of the Vanilloid (VR1) receptor is beneficial, particularly the Disorders of the Invention.

In order to use the compounds of the invention in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. Thus, the present invention also provides a
20 pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient therefor.

A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is
25 usually adapted for oral, parenteral, rectal administration or intravesical administration to the bladder and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions, suspensions or suppositories. Orally administrable compositions are generally preferred.

30 Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets

may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. For systemic administration, dosage levels from 0.01mg to 100mg per kilogramme of body weight are useful in the treatment of pain. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20, 20 to 250, or 0.1 to 500.0 mg, for example 0.2 to 5 and 0.1 to 250 mg; and such unit doses may be administered

more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 1000 mg; and such therapy may extend for a number of weeks or months.

5 No unacceptable toxicological effects are indicated with compounds of the invention when administered in accordance with the invention.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

10 The following Descriptions and Examples illustrate the preparation of the compounds of the invention.

Abbreviations

15 BINAP – 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl

HPLC – High Performance Liquid Chromatography

MgSO₄ - Magnesium sulfate

TFA – Trifluoroacetic acid

DCM - dichloromethane

20

Description 1

[(R)-1-(5-Trifluoromethylpyridin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester (D1)

25

To a solution of 2-chloro-5-trifluoromethylpyridine (7.3g, 0.04mol) and 3*R*-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine (7.5g, 0.04mol) in dry dimethylformamide (100ml) was added powdered potassium carbonate (6.6g, 0.05mol) and the reaction heated at 100°C for 7h and cooled. Solvent was
30 removed under reduced pressure and the residue partitioned between ethyl acetate and water. The organic phase was separated, dried (MgSO₄) and filtered. Removal of solvent under reduced pressure gave a solid.

Chromatography on silica gel eluting with ethyl acetate and DCM (gradient elution, 20% maximum) afforded the title compound as a white solid.

Description 2

5 (R)-1-(5-Trifluoromethylpyridin-2-yl)-pyrrolidin-3-ylamine (D2)

A solution of D1 (11.5g, 0.04mol) in DCM (80ml) was cooled (ice-bath) and trifluoroacetic acid (excess, 50ml) was added. Reaction was warmed to ambient temperature, stirred for 3h and partitioned between ethyl acetate and
10 aqueous sodium hydroxide. The organic phase was separated, dried (MgSO₄) and filtered. Removal of solvent under reduced pressure afforded the crude product as a yellow oil. Bulb to bulb distillation under reduced pressure initially afforded the title compound as an oil which crystallised on standing.

15 Description 3

1,3-Dimethyl-5-nitroisoquinoline (D3)

1,3-Dimethylisoquinoline [(*Chem. Lett.*, 1983, p.791), 2.39g, 15.20mM], in concentrated sulfuric acid, (15ml), was cooled to <4°C. A solution of potassium
20 nitrate, (1.69g, 16.72mM), in concentrated sulfuric acid was added dropwise, maintaining the temperature below 4°C. After complete addition the solution was stirred at this temperature for a further 2h then warmed to room temperature for 1h. The reaction mixture was poured into ice water and the solution basified with sodium hydroxide and extracted with DCM. The extract was washed with brine,
25 dried and concentrated to a yellow solid. Purification by silica gel chromatography afforded the title compound as a yellow crystalline solid.

Description 4

5-Amino-1,3-dimethylisoquinoline (D4)

30

A solution of D3 (2.01g, 9.94mM) and 10% palladium on charcoal (1g) in methanol was hydrogenated at atmospheric pressure for 1h. The catalyst was

filtered off and the filtrate concentrated under reduced pressure to afford the title compound as an off white solid.

Description 5

5 3-Methyl-5-nitroisoquinoline (D5)

A solution of 3-methylisoquinoline (5.4g, 0.038mol) in concentrated sulfuric acid (30ml) was cautiously added to a solution of potassium nitrate (4.25g, 1.1eq) in concentrated sulfuric acid (23ml) whilst maintaining the
10 temperature below 4°C (ice bath). Stirring was continued for 2h and then temperature raised to ambient. Reaction was further stirred for 3h and then poured into ice-water slurry (500ml). Neutralisation using solid potassium carbonate afforded a yellow solid which was filtered and washed with water. The crude product was dissolved in ethanol (200ml), filtered and concentrated under
15 reduced pressure to afford the title compound as a yellow solid.

Description 6

5-Amino-3-methylisoquinoline (D6)

20 The title compound was prepared from D5 using the procedure outlined for Description 4.

Description 7

***N*-(2,2-Dimethoxyethyl)-(1-phenyl)ethylamine (D7)**

25

A solution of α -methylbenzylamine (8.37g, 0.07mol) and bromoacetaldehyde dimethylacetal (11.67g, 0.07mol) in acetonitrile (150ml) containing potassium carbonate (12.39g, 0.09mol) was heated at reflux for 2d and cooled. The solid was filtered off and the filtrate was concentrated under
30 reduced pressure to leave an oil. Chromatography on silica gel eluting with ethyl acetate afforded the title compound as an oil.

Description 8**1-Methylisoquinoline (D8)**

To cooled chlorosulfonic acid (16ml, -10°C) was cautiously added D7 (5g, 0.024mol) over a period of 2h. Reaction was allowed to warm to ambient temperature and stirring continued for 3d. The reaction was then poured into ice-water slurry (500ml), basified using solid potassium carbonate followed by extraction using DCM. Organic phase was separated, dried over MgSO₄, filtered and concentrated under reduced pressure to leave an oil. Chromatography on silica gel eluting with ethyl acetate afforded the title compound as yellow oil.

Description 9**1-Methyl-5-nitroisoquinoline (D9)**

A solution D8 (1g, 7mmol) in sulfuric acid (2.5ml) was cooled (<4°C) and concentrated nitric acid (1ml) added over 10min. Reaction was stirred for 30min and then heated at 60°C for 2h. After cooling the reaction mixture was poured into ice water slurry (100ml) and basified using solid potassium carbonate followed by extraction using DCM. Organic phase was separated, dried over MgSO₄, filtered and concentrated under reduced pressure to afford the title compound as a white solid.

Description 10**5-Amino-1-methylisoquinoline (D10)**

The title compound was prepared from (D9) using the procedure outlined for Description 4.

Description 11**((R)-1-(3-Methylphenyl)pyrrolidin-3-yl)carbamic acid *tert*-butyl ester (D11)**

A suspension of BINAP 1.25g, 2mmol), palladium acetate (0.3g, 1.3mmol)
5 cesium carbonate (6.6g, 0.02mol), 3-bromotoluene (4.6g, 0.027mol) and (3*R*)-
(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine (2.5g, 0.013mol) in 1,4-dioxane
(anhydrous, 50ml) was heated at reflux under an argon atmosphere for 18h.
After cooling, solvent was removed under reduced pressure and residue
partitioned between DCM and water. Organic phase was separated, dried over
10 MgSO₄, filtered and concentrated under reduced pressure to leave an oil.
Chromatography on silica gel eluting with ethyl acetate and hexane (gradient
elution, maximum 4%) afforded the title compound as an off-white solid.

Description 12**(R)-1-(3-Methylphenyl)pyrrolidin-3-ylamine (D12)**

A solution of D11 (2.07g, 7.5mmol) in TFA (1.2ml) and DCM (20ml) was
stirred at ambient temperature for 18h. Solvent was removed under reduced
pressure and the residue partitioned between DCM and aqueous sodium
20 hydrogen carbonate. Organic phase was separated, dried over MgSO₄, filtered
and concentrated under reduced pressure to afford the title compound as an oil.

Description 13**(R)-1-(3-Fluorophenylpyrrolidin-3-yl)carbamic acid *tert*-butyl ester (D13)**

25

The title compound was prepared from (3*R*)-(+)-3-(*tert*-
butoxycarbonylamino)pyrrolidine and 1-bromo-3-fluorobenzene using the
procedure outlined in Description 11.

30

Description 14**(R)-1-(3-Fluorophenyl)pyrrolidin-3-ylamine (D14)**

5 The title compound was prepared from D13 using the procedure outlined for Description 12.

Description 15**(R)-1-(3,4-Difluorophenyl)pyrrolidine-3-carbamic acid *tert*-butyl ester (D15)**

10 The title compound was prepared from (3*R*)-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine and 4-bromo-1,2-difluorobenzene using the procedure outlined for Description 11.

Description 16

15 **(R)-1-(3,4-Difluorophenyl)-pyrrolidin-3-ylamine(D16)**

 The title compound was prepared from D15 using the procedure outlined for Description 12.

20 **Description 17**

(R)-1-(3-Fluoro-4-methylphenyl)pyrrolidine-3-carbamic acid *tert*-butyl ester (D17)

25 The title compound was prepared from (3*R*)-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine and 4-bromo-2-fluorotoluene using the procedure outlined for Description 11.

Description 18

30 **(R)-1-(3-Fluoro-4-methylphenyl)-pyrrolidin-3-ylamine(D18)**

 The title compound was prepared from D17 using the procedure outlined for Description 12.

Description 19**(2,2-Diethoxyethyl)-(2-fluorobenzylidene)amine (D19)**

2-Fluorobenzaldehyde (7.45g), was added to aminoacetaldehyde
5 diethylacetal (9.16g) and the reaction heated to 100°C for 3h. After cooling, the mixture was transferred to a separating funnel and partitioned between diethyl ether and water. The ether layer was separated, dried over magnesium sulfate, filtered and concentrated under reduced pressure to leave an oil. Distillation at 0.6-0.8mm collecting the fraction boiling at 102-106°C afforded the title
10 compound as a colourless oil.

Description 20**8-Fluoroisoquinoline (D20)**

15 A solution of phosphorus pentoxide, (18g), in concentrated sulfuric acid, (5 ml), was heated to 160°C was treated cautiously with a solution of D19 (11.5g) concentrated sulfuric acid, (75ml) over a period of 5 mins. After heating for 25 mins the reaction was cooled and poured into ice-water slurry (1l). Basification with solid sodium hydroxide to pH 10 was followed by extraction with ethyl
20 acetate. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure to afford the crude product. Chromatography on silica gel eluting with ethyl acetate and hexane (gradient, max 10%) afforded the product as a pale yellow crystalline solid.

25 Description 21**8-Fluoro-5-nitroisoquinoline (D21)**

D20, (0.278g), in concentrated sulfuric acid, (2ml), was cooled to 0°C. Potassium nitrate, (0.21g), was added portionwise whilst maintaining the
30 temperature below 0°C. After complete addition the solution was stirred at 0°C for a further 1.5h and then stirred at ambient temperature for 24h. The reaction mixture was poured into ice-water slurry, basified with sodium hydroxide and

extracted with ethyl acetate. The ethyl acetate solution was dried over magnesium sulfate, filtered and concentrated under reduced pressure to leave the crude product. Purification by silica gel chromatography eluting with ethyl acetate afforded the title compound as a yellow crystalline solid.

5

Description 22**5-Amino-8-fluoroisoquinoline (D22)**

D21, (0.283g), in ethanol (2ml), was treated with concentrated hydrochloric acid, (2ml). Reaction mixture cooled in an ice bath and a solution of tin (II) chloride dihydrate, (1.45g), in ethanol, (2ml), was added portionwise over 10 mins. After a further 20mins the reaction mixture was basified with sodium hydroxide and extracted with DCM. The DCM solution was dried over magnesium sulfate, filtered and concentrated under reduced pressure to leave the crude product. Chromatography on silica gel eluting with ethyl acetate gave the title compound as a cream solid.

15

Description 23**(1-Benzyl-piperidin-4-yl)-carbamic acid *tert*-butyl ester (D23)**

20

To a solution of 1-benzyl-4-aminopiperidine (30g, 0.16mol) in DCM (200ml) was added dropwise a solution of di-*tert*-butyl dicarbonate (1.1eq., 37.9g) in DCM (100ml) over a period of 2h. Reaction was stirred at ambient temperature for 18h and then solvent was removed under reduced pressure to afford the title compound as a white solid.

25

Description 24**Piperidin-4-yl-carbamic acid *tert*-butyl ester (D24)**

30

A solution of D23 (10g, 3.4mmol) in methanol (150ml) was hydrogenated at 50psi in a Parr hydrogenator using 10% Palladium on carbon catalyst (800mg)

for 18h. Catalyst was filtered off and the filtrate concentrated under reduced pressure to afford the title compound as a white solid.

Description 25

- 5 **1-(((5-Trifluoromethylpyridin-2-yl)piperidin-4-yl)amino)-carbamic acid *tert*-butyl ester (D25)**

The title compound was prepared from D24 and 2-chloro-5-trifluoromethylpyridine using the procedure outlined for Description 1.

10

Description 26

- 1-(5-Trifluoromethylpyridin-2-yl)-piperidin-4-ylamine (D26)**

- 15 The title compound was prepared from D25 using the procedure outlined for Description 2.

Description 27

- 3-(3'-Isoquinolin-5-yl-ureido)-piperidine-1-carboxylic acid *tert*-butyl ester (D27)**

20

- To a suspension of 1-(*tert*-butoxycarbonyl)-3-piperidine carboxylic acid (1g, 4.4mmol) in toluene (10ml) and triethylamine (0.68ml) was added diphenylphosphoryl azide (1.1eq., 1.33g). Reaction was heated at reflux for 1h and cooled. 5-Aminoisoquinoline (629mg, 4.4mmol) was added and reaction
25 stirred at ambient temperature for 56h. Solvent was removed under reduced pressure and the residue chromatographed on silica gel eluting with hexane/ethyl acetate (gradient elution, maximum 50%) to afford the title compound as a foam.

30

Description 28***N*-(Isoquinolin-5-yl)-*N'*-(piperidin-3-yl)-urea (D28)**

5 The title compound was prepared from D27 using the procedure outlined for Description 2.

Description 29***[(R)*-1-(3-Trifluoromethylpyridin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester (D29)**

10

The title compound was prepared from 2-chloro-3-trifluoromethylpyridine and 3*R*-(+)-3-(*tert*-butyloxycarbonylamino)pyrrolidine using the procedure outlined for Description 1.

15 **Description 30*****(R)*-1-(3-Trifluoromethylpyridin-2-yl)-pyrrolidin-3-ylamine(D30)**

20 The title compound was prepared from D29 using the procedure outlined for Description 2.

20

Description 31***[(R)*-1-(4-Trifluoromethylpyridin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester (D31)**

25 The title compound was prepared from 2-chloro-4-trifluoromethylpyridine and 3*R*-(+)-3-(*tert*-butyloxycarbonylamino)pyrrolidine using the procedure outlined for Description 1.

30

Description 32**(R)-1-(4-Trifluoromethylpyridin-2-yl)-pyrrolidin-3-ylamine (D32)**

5 The title compound was prepared from D31 using the procedure outlined for Description 2.

Description 33**[(R)-1-(6-Trifluoromethylpyridin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester (D33)**

10

The title compound was prepared from 2-chloro-6-trifluoromethylpyridine and 3*R*-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine using the procedure outlined for Description 1.

15 **Description 34****(R)-1-(6-Trifluoromethylpyridin-2-yl)-pyrrolidin-3-ylamine(D34)**

The title compound was prepared from D33 using the procedure outlined for Description 2.

20

Description 35**[(R)-1-(3-Chloropyridin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester (D35)**

25 The title compound was prepared from 2,3-dichloropyridine and 3*R*-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine using the procedure outlined for Description 1.

30

Description 36**(R)-1-(3-Chloropyridin-2-yl)-pyrrolidin-3-ylamine(D36)**

5 The title compound was prepared from D35 using the procedure outlined for Description 2.

Description 37**[(R)-1-(5-Chloropyridin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester (D37)**

10

 The title compound was prepared from 2,5-dichloropyridine and 3*R*-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine using the procedure outlined for Description 1.

15 **Description 38****(R)-1-(5-Chloropyridin-2-yl)-pyrrolidin-3-ylamine (D38)**

 The title compound was prepared from D37 using the procedure outlined for Description 2

20

Description 39**[(R)-1-(5-Bromopyridin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester (D39)**

25 The title compound was prepared from 2-chloro-5-bromopyridine and 3*R*-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine using the procedure outlined for Description 1.

30

Description 40**(R)-1-(5-Bromopyridin-2-yl)-pyrrolidin-3-ylamine (D40)**

5 The title compound was prepared from D39 using the procedure outlined for Description 2.

Description 41**[(R)-1-(6-Methylpyridin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester (D41)**

10

 The title compound was prepared from 2-chloro-6-methylpyridine and 3*R*-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine using the procedure outlined for Description 1.

15 **Description 42****(R)-1-(6-Methylpyridin-2-yl)-pyrrolidin-3-ylamine (D42)**

 The title compound was prepared from D41 using the procedure outlined for Description 2

20

Description 43**1-[(3-Trifluoromethylpyridin-2-yl)piperidin-4-yl]amino]-carbamic acid *tert*-butyl ester (D43)**

25 The title compound was prepared from D24 and 2-chloro-3-trifluoromethylpyridine using the procedure outlined for Description 1.

Description 44**1-(3-Trifluoromethylpyridin-2-yl)-piperidine-4-ylamine (D44)**

30

 The title compound was prepared from D43 using the procedure outlined for Description 2.

Description 45

1-(((6-Trifluoromethylpyridin-2-yl)piperidin-4-yl)amino]-carbamic acid *tert*-butyl ester (D45)

5 The title compound was prepared from D24 and 2-chloro-6-trifluoromethylpyridine using the procedure outlined for Description 1.

Description 46

1-(6-Trifluoromethylpyridin-2-yl)-piperidin-4-ylamine (D46)

10

 The title compound was prepared from D45 using the procedure outlined for Description 2.

Description 47

15 **1-(((4-Trifluoromethylpyridin-2-yl)piperidin-4-yl)amino]-carbamic acid *tert*-butyl ester (D47)**

 The title compound was prepared from D24 and 2-chloro-4-trifluoromethylpyridine using the procedure outlined for Description 1.

20

Description 48

1-(4-Trifluoromethylpyridin-2-yl)-piperidin-4-ylamine(D48)

25 The title compound was prepared from D47 using the procedure outlined for Description 2.

Description 49

1-(((3-Chloro-5-trifluoromethylpyridin-2-yl)piperidin-4-yl)amino]-carbamic acid *tert*-butyl ester (D49)

30

 The title compound was prepared from D24 and 2,3-dichloro-5-trifluoromethylpyridine using the procedure outlined for Description 1.

Description 50**1-(3-Chloro-5-trifluoromethylpyridin-2-yl)-piperidin-4-ylamine (D50)**

The title compound was prepared from D49 using the procedure outlined
5 for Description 2.

The following amines were prepared using methods to those described above.

(R)-1-(3-Methylpyridin-2-yl)-pyrrolidin-3-ylamine (D51).

10

(R)-1-(4-Methylpyridin-2-yl)-pyrrolidin-3-ylamine (D52).


(R)-1-(5-Methylpyridin-2-yl)-pyrrolidin-3-ylamine (D53).

15 **(R)-1-(6-Methoxypyridin-2-yl)-pyrrolidin-3-ylamine (D54).**

1-(3-Cyano-5-trifluoromethylpyridin-2-yl)-piperidin-4-ylamine (D55).

(3*R*)-(+)-3-(*tert*-butoxycarbonylamino)pyrrolidine, 5-aminoisoquinoline, 1-
20 aminoisoquinoline, 5-aminoquinoline and 7-aminoquinoline are available
commercially from TCI (Japan), Aldrich Chemical Company and Specs and
BioSpecs B.V. respectively. Di-*tert*-butyl tricarboxylate was prepared according to
the procedure outlined in the literature (Org. Synth., 1978, 57, p.45). 2-methyl-7-
aminoquinoline was prepared according to the procedure outlined in the literature
25 (J Med. Chem., 1977, 20(11), p.1528).

30

Example 1***N*-(2-Bromophenyl)-*N'*-[*[(R)*-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)]urea (E1)**

5


A solution of 2-bromophenyl isocyanate (Aldrich Chemical Company) (27.4ml, 0.222mol) in dry diethyl ether (65ml) was added dropwise over 0.5h to an efficiently stirred solution of D2 (51.4g, 0.222mol) in dry diethyl ether (0.8L) under argon at ambient temperature. After stirring for 18h, a white precipitate was filtered off and washed with dry diethyl ether (2 x 150ml). The solid was crushed to a fine powder and then re-stirred with diethyl ether (470ml) for 4h at ambient temperature. The insoluble product was filtered off, washed with diethyl ether (100ml) and dried at 50°C/vacuum/24h to afford title compound as a white solid.

15

¹H NMR (d₆-DMSO, 400MHz) δ 1.94-1.98 (1H, m), 2.19-2.28 (1H, m), 3.31-3.41 (1H, m), 3.56 (2H, br, s), 3.67-3.71 (1H, m), 4.34-4.36 (1H, m), 6.62 (1H, d, J 9.0Hz), 6.89 (1H, t, J 7.8Hz), 7.28 (1H, t, J 8.5Hz), 7.47 (1H, d, J 6.7Hz), 7.55 (1H, dd, J 8.0, 1.4Hz), 7.76-7.79 (2H, m), 8.12 (1H, dd, J 8.3, 1.4Hz), 8.41 (1H, s). MH⁺ 429, 431.

20


25

Example 2***N*-(Isoquinol-5-yl)-*N'*-[*((R)*-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)]urea (E2)**

5

To a solution of di-*tert*-butyl tricarboxylate, (0.681g, 2.595mmol), in dry DCM (1ml) was added a solution of D2, (0.5g, 2.162mmol) in in dry DCM (1ml) in one portion. After the initial effervescence, the solution was stirred at room temperature for 0.3h. A solution of 5-aminoisoquinoline, (0.312g, 2.162mmol) in dry DCM (1ml) was added. The reaction mixture was stirred at room temperature overnight. The resultant precipitate was removed by centrifugation, and the solid washed with ether and dried to give the title compound as a white solid.


¹H NMR (d₆-DMSO, 250MHz) δ 9.26 (1H, s), 8.57 (1H, s), 8.52 (1H, d), 8.41(1H,s), 8.31 (1H,d), 7.88 (1H, d), 7.78 (1H,dd), 7.70 (1H, d), 7.60 (1H, t), 6.99 (1H, d), 6.64 (1H, d), 4.41 (1H, m), 3.73 (1H, dd), 3.59 (2H, m), 3.42 (1H, m), 2.28 (1H, m) and 2.02 (1H, m). MH⁺ 402

20 **Example 3****(±)-*N*-(Isoquinol-5-yl)-*N'*-[(1-(5-trifluoromethyl-2-pyridyl)piperidin-3-yl)]urea (E3)**

D28 (0.2g, 0.74mmol), 2-chloro-5-trifluoromethylpyridine (3eq., 0.4g) in dimethylformamide (10ml) and finely powdered potassium carbonate (3eq. 0.31g) were heated at 90°C for 18h and cooled. Solvent was removed under reduced pressure and the residue partitioned between ethyl acetate and water. The organic phase was separated, dried (MgSO₄) and filtered. Removal of solvent under reduced pressure afforded the crude product. This was chromatographed on silica gel eluting with ethyl acetate to give the title compound as an off-white solid which was converted into a hydrochloride salt. MH⁺ (free base) 416.



















The two enantiomers (E3A and E3B) were separated by HPLC using Chiralpak AD column (250x19mm id), and eluting with n-hexane:ethanol (80:20 v/v) at a flow rate of 1ml/min with UV detection at 215nm.

















Examples presented in Table 1 were prepared in accordance with the procedures described herein and similar to those of E1 to E3.















Table 1



















5

















Ex		S'Chem	s	r		MH+
4		R	1	1		429, 431
5		R	1	1		429, 431
6		R	1	1		429, 431
7		R	1	1		396, 398
8		R	1	1		396, 398















9		R	1	1		440, 442
10		R	1	1		477
11		R	1	1		385, 387
12		R	1	1		407
13		R	1	1		373, 375
14		R	1	1		353
15		R	1	1		369
16		R	1	1		384, 386
17		R	1	1		452, 454

















18		R	1	1		452, 454
19		R	1	1		420, 422
20		R	1	1		402
21		R	1	1		402
22		R	1	1		402
23		R	1	1		368, 370
24		R	1	1		347
25		R	1	1		351



















26		R	1	1		365
27		R	1	1		369
28		R	1	1		416
29		R	1	1		380, 382
30		R	1	1		361
31		R	1	1		365
32		R	1	1		383







33		R	1	1		379
34		R	1	1		416
35		R	1	1		416
36		R	1	1		416
37		R	1	1		416
38		R	1	1		381, 383
39		R	1	1		380, 382
40		R	1	1		361
41		R	1	1		365

42		R	1	1		382
43		R	1	1		379
44		R	1	1		362
45		R	1	1		362
46		R	1	1		362
47		R	1	1		362
48		R	1	1		378
49		R	1	1		430

50		R	1	1		396, 398
51		R	1	1		375
52		R	1	1		379
53		R	1	1		397
54		R	1	1		393
55		R	1	1		395, 397
56		R	1	1		430

57		R	1	1		430
58		R	1	1		430
59		R	1	1		420
60			1	2		416
61			1	2		416
62		-	2	1		416
63		-	2	1		416
64		-	2	1		416

65		-	2	1		416
66		-	2	1		416
67		-	2	1		416
68		-	2	1		416
69		-	2	1		430
70		-	2	1		463, 465
71		-	2	1		430
72		-	2	1		455
74		-	2	1		430

75		-	2	1		430
76		S	1	1		429, 431
77		R	1	1		417

S'Chem = stereochemistry

5

10

15

20

25

Pharmacological Data

(a) In vitro assay

As referenced above, the compounds of the invention are vanilloid
5 receptor (VR1) antagonists and hence have useful pharmaceutical properties.
Vanilloid receptor (VR1) antagonist activity can be confirmed and demonstrated
for any particular compound by use of conventional methods, for example those
disclosed in standard reference texts such as D. Le Bars, M. Gozarin and S. W.
Cadden, Pharmacological Reviews, 2001, 53(4), 597-652] or such other texts
10 mentioned herein.

The screen used for the compounds of this invention was based upon a
FLIPR based calcium assay, similar to that described by Smart et al. (British
Journal of Pharmacology, 2000, 129, 227-230). Transfected astrocytoma
1321N1 cells, stably expressing human VR1, were seeded into FLIPR plates at
15 25,000cells/well (96-well plate) and cultured overnight.

The cells were subsequently loaded in medium containing 4 μ M Fluo-3
AM (Molecular Probes) for 2 hours, at room temperature, in the dark. The plates
were then washed 4 times with Tyrode containing 1.5mM calcium, without
probenecid. The cells were pre-incubated with compound or buffer control at
20 room temperature for 30 minutes. Capsaicin (Sigma) was then added to the
cells. Compounds having antagonist activity against the human VR1 were
identified by detecting differences in fluorescence when measured after
capsaicin addition, compared with no compound buffer controls. Thus, for
example, in the buffer control capsaicin addition results in an increase in
25 intracellular calcium concentration resulting in fluorescence. A compound having
antagonist activity blocks the capsaicin binding to the receptor, there is no
signalling and therefore no increase in intracellular calcium levels and
consequently lower fluorescence. pK_b values are generated from the IC₅₀
values using the Cheng-Prusoff equation.

30 All compounds tested by the above methodology had pK_b > 6, preferred
compounds having a pK_b > 7.0.

(b) FCA-induced hyperalgesia in the Guinea pig

100µl of 1mg/ml FCA was injected intraplantar into the left paw of 4 groups of 8 male Dunkin Hartley guinea-pigs (batch: 6282434, average weight 340g). 24 hours later compounds were administered orally at 0 (vehicle), 3, 10 30mg/kg with vehicle as 1% methylcellulose and dosing volume being 2ml/kg and dosing straight into the stomach. The methylcellulose was added gradually to the compound into the pestle and mortar and ground together.

Behavioural readouts of mechanical hyperalgesia were obtained before FCA administration (naïve reading), after FCA but before drug administration (predose reading) and 1 hour after drug administration. The readout used was paw pressure (Randall-Sellito) and the end point was paw withdrawal. The paw pressure equipment also had one silver disc placed on the point to increase the markings by a factor of 2.

Compounds having a $pK_b > 7.0$ *in vitro*, according to model (a) above, were tested in this model and shown to be active.

20


25

30

Claims

1. A compound of formula (I),

5



(I)

or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:

P and P' are independently selected from aryl and heteroaryl;

- 10 R¹ and R² are independently selected from -H, halo, alkyl, alkoxy, cycloalkyl, aralkyl, aralkoxy, cycloalkylalkyl, cycloalkylalkoxy, -CN, -NO₂, -OH, -OCF₃, -CF₃, -NR⁴R⁵, -S(O)_mR⁶, -S(O)₂NR⁴R⁵, -OS(O)₂R⁶, -OS(O)₂CF₃, -O(CH₂)_xNR⁴R⁵, -C(O)CF₃, -C(O)alkyl, -C(O)cycloalkyl, -C(O)aralkyl, -C(O)Ar, -C(O)(CH₂)_xOR⁶, -C(O)(CH₂)_xNR⁴R⁵, -C(O)alkoxy, -C(O)NR⁴R⁵, -(CH₂)_xC(O)alkoxy, -
- 15 (CH₂)_xOC(O)R⁶, -(CH₂)_xOR⁶, -(CH₂)_xR⁴R⁵, -(CH₂)_xC(O)NR⁴R⁵, -(CH₂)_xN(R⁴)C(O)R⁶, -(CH₂)_xS(O)₂NR⁴R⁵, -(CH₂)_xN(R⁴)S(O)₂R⁶, -ZAr, -(CH₂)_xS(O)₂R⁶, -(OCH₂)_xS(O)₂R⁶, -N(R⁴)S(O)₂R⁶, -N(R⁴)C(O)R⁶, -(CH₂)_xN(R⁴)S(O)₂R⁶, -(CH₂)_xN(R⁴)C(O)R⁶ or -(CH₂)_xC(O)alkyl;

R⁴ and R⁵ may be the same or different and represent H or alkyl or R⁴ and R⁵

- 20 together with the atoms to which they are attached form a C₃₋₆azacycloalkane, C₃₋₆(2-oxo)azacycloalkane ring or C₅₋₈ polymethylene chain optionally interrupted by heteroatoms such as O or -NR⁷.

Z is O, S or NR⁷;

R⁶ is alkyl or aryl;

- 25 R⁷ is hydrogen, alkyl or aryl;

m is 1 or 2;

n is 0, 1, 2 or 3;

p and q are independently 0, 1, 2, 3 or 4;

r is 1, 2 or 3;

s is 0, 1 or 2; and

x is 0, 1, 2, 3, 4, 5 or 6;


with the proviso that said compound of formula (I) is not a compound selected from:

- 1- (1-phenyl-3-pyrrolidinyl)-3-phenyl urea;
- 1- (1-phenyl-3-pyrrolidinyl)-3- (4-methoxyphenyl)urea;
- N*- (4-Fluorophenyl)-*N'*- [((*R*) - 1- ((3-methylphenyl)pyrrolidin-2-ylmethyl))]urea;
- N*- (2-Bromophenyl)-*N'*- [((*R*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- 10 *N*- (2-Bromophenyl)-*N'*- [((*R*) - 1- (3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*- (4-Fluorophenyl)-*N'*- [((*S*) - 1- (3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*- (2-Bromophenyl)-*N'*- [((*S*) - 1- (3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
- N*- (4-Fluorophenyl)-*N'*- [((*S*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*- (2-Bromophenyl)-*N'*- [((*S*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- 15 *N*- (4-Fluorophenyl)-*N'*- [((*R*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*- (4-Fluorophenyl)-*N'*- [((*R*) - 1- (3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*- (2-Bromophenyl)-*N'*- [((*R*) - 1- (3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*- (1-Naphthyl)-*N'*- [((*R*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*- (2,3-Dichlorophenyl)-*N'*- [((*R*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- 20 *N*- (2-Bromophenyl)-*N'*- [((*S*) - 1- (3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*- (2-Bromophenyl)-*N'*- [((*R*) - 1- (4-fluoro-3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*- (2-Bromophenyl)-*N'*- [((*R*) - 1- (3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- N*- (2-Bromophenyl)-*N'*- [((*R*) - 1- (3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea;
- N*- (3-Chloro-2-methylphenyl)-*N'*- [((*R*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- 25 *N*- (2,3-Dichlorophenyl)-*N'*- [((*R*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*- (2,5-Dichlorophenyl)-*N'*- [((*R*) - 1- (3-methylphenyl)pyrrolidin-3-yl)]urea;
- N*- (2,3-Dichlorophenyl)-*N'*- [((*R*) - 1- (3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*- (2,5-Dichlorophenyl)-*N'*- [((*R*) - 1- (3-fluorophenyl)pyrrolidin-3-yl)]urea;
- N*- (3-Chloro-2-methylphenyl)-*N'*- [((*R*) - 1- (3-fluorophenyl)pyrrolidin-3-yl)]urea;
- 30 *N*- (3-Chloro-2-methylphenyl)-*N'*- [((*R*) - 1- (3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- N*- (2,3-Dichlorophenyl)-*N'*- [((*R*) - 1- (3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
- N*- (2,5-Dichlorophenyl)-*N'*- [((*R*) - 1- (3,4-difluorophenyl)pyrrolidin-3-yl)]urea;

N-(3-Chloro-2-methylphenyl)-*N'*-[((*R*)-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea; and

N-(2,3-Dichlorophenyl)-*N'*-[((*R*)-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea.

- 5 2. A compound of formula (I), as claimed in claim 1, or formula (IA),



- 10 or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:
P is phenyl, naphthyl, quinoliny or isoquinoliny;
P' is phenyl or pyridyl;
R¹ and R² are independently selected from -H, halo, alkyl, alkoxy, cycloalkyl,
aralkyl, aralkoxy, cycloalkylalkyl, cycloalkylalkoxy, -CN, -NO₂, -OH, -OCF₃, -CF₃,
15 -NR⁴R⁵, -S(O)_mR⁶, -S(O)₂NR⁴R⁵, -OS(O)₂R⁶, -OS(O)₂CF₃, -O(CH₂)_xNR⁴R⁵,
-C(O)CF₃, -C(O)alkyl, -C(O)cycloalkyl, -C(O)aralkyl, -C(O)Ar, -C(O)(CH₂)_xOR⁶, -
C(O)(CH₂)_xNR⁴R⁵, -C(O)alkoxy, -C(O)NR⁴R⁵, -(CH₂)_xC(O)alkoxy, -
(CH₂)_xOC(O)R⁶, -(CH₂)_xOR⁶, -(CH₂)_xR⁴R⁵, -(CH₂)_xC(O)NR⁴R⁵, -
(CH₂)_xN(R⁴)C(O)R⁶, -(CH₂)_xS(O)₂NR⁴R⁵, -(CH₂)_xN(R⁴)S(O)₂R⁶, -ZAr, -
20 (CH₂)_xS(O)₂R⁶, -(OCH₂)_xS(O)₂R⁶, -N(R⁴)S(O)₂R⁶, -N(R⁴)C(O)R⁶, -
(CH₂)_xN(R⁴)S(O)₂R⁶, -(CH₂)_xN(R⁴)C(O)R⁶ or -(CH₂)_xC(O)alkyl;
R⁴ and R⁵ may be the same or different and represent H or alkyl or R⁴ and R⁵
together with the atoms to which they are attached form a C₃₋₆azacycloalkane,
C₃₋₆(2-oxo)azacycloalkane ring or C₅₋₈ polymethylene chain optionally interrupted
25 by heteroatoms such as O or -NR⁷.
Z is O, S or NR⁷;
R⁶ is alkyl or aryl;
R⁷ is hydrogen, alkyl or aryl;

m is 1 or 2;

n is 0, 1, 2 or 3;

p and q are independently 0, 1, 2, 3 or 4;

r is 1, 2 or 3;

5 s is 0, 1 or 2; and

x is 0, 1, 2, 3, 4, 5 or 6;

with the proviso that the compound of formula (I) is not a compound selected from:

1-(1-phenyl-3-pyrrolidinyl)-3-phenyl urea;

10 1-(1-phenyl-3-pyrrolidinyl)-3-(4-methoxyphenyl)urea;

N-(4-Fluorophenyl)-*N'*-[*((R)*-1-((3-methylphenyl)pyrrolidin-2-ylmethyl))]urea;

N-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;

N-(4-Fluorophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;

15 *N*-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;

N-(4-Fluorophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(4-Fluorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(4-Fluorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

20 *N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

N-(1-Naphthyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-*N'*-[*((R)*-1-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)]urea;

25 *N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;

N-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea;

N-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;

N-(2,5-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;


30 *N*-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

N-(2,5-Dichlorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

N-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;

- N*-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
N-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
N-(2,5-Dichlorophenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
N-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea; and
N-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea.

3. A compound of formula (I), as claimed in claim 1, of formula (IB),



or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:

P is phenyl, naphthyl, quinoliny or isoquinoliny;


- R¹ and R² are independently selected from -H, halo, alkyl, alkoxy, cycloalkyl,
 15 aralkyl, aralkoxy, cycloalkylalkyl, cycloalkylalkoxy, -CN, -NO₂, -OH, -OCF₃, -CF₃,
 -NR⁴R⁵, -S(O)_mR⁶, -S(O)₂NR⁴R⁵, -OS(O)₂R⁶, -OS(O)₂CF₃, -O(CH₂)_xNR⁴R⁵,
 -C(O)CF₃, -C(O)alkyl, -C(O)cycloalkyl, -C(O)aralkyl, -C(O)Ar, -C(O)(CH₂)_xOR⁶, -
 C(O)(CH₂)_xNR⁴R⁵, -C(O)alkoxy, -C(O)NR⁴R⁵, -(CH₂)_xC(O)alkoxy, -
 (CH₂)_xOC(O)R⁶, -(CH₂)_xOR⁶, -(CH₂)_xR⁴R⁵, -(CH₂)_xC(O)NR⁴R⁵, -
 20 (CH₂)_xN(R⁴)C(O)R⁶, -(CH₂)_xS(O)₂NR⁴R⁵, -(CH₂)_xN(R⁴)S(O)₂R⁶, -ZAr, -
 (CH₂)_xS(O)₂R⁶, -(OCH₂)_xS(O)₂R⁶, -N(R⁴)S(O)₂R⁶, -N(R⁴)C(O)R⁶, -
 (CH₂)_xN(R⁴)S(O)₂R⁶, -(CH₂)_xN(R⁴)C(O)R⁶ or -(CH₂)_xC(O)alkyl;

- R⁴ and R⁵ may be the same or different and represent H or alkyl or R⁴ and R⁵
 together with the atoms to which they are attached form a C₃₋₆azacycloalkane,
 25 C₃₋₆(2-oxo)azacycloalkane ring or C₅₋₈ polymethylene chain optionally interrupted
 by heteroatoms such as O or -NR⁷.

Z is O, S or NR⁷;

R⁶ is alkyl or aryl;


- R^7 is hydrogen, alkyl or aryl;
 m is 1 or 2;
 n is 0, 1, 2 or 3;
 p and q are independently 0, 1, 2, 3 or 4;
 5 r is 1, 2 or 3;
 s is 0, 1 or 2; and
 x is 0, 1, 2, 3, 4, 5 or 6;
4. A compound of formula (IB) as claimed in claim 3, wherein:
 10 R^1 and R^2 are independently selected from halo, hydroxy, alkyl, alkoxy, $-CF_3$, $-NO_2$, $-CN$, $-OCF_3$, amino or mono- or dialkylamino;
 p and q are independently 0, 1 or 2; and
 r and s are independently 1 or 2.
- 15 5. A compound of formula (I), as claimed in claim 1, of formula (IC),



- or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:
 20 P is phenyl, naphthyl, quinolinyl or isoquinolinyl;
 R^1 and R^2 are independently selected from halo, hydroxy, alkyl, alkoxy, $-CF_3$, $-NO_2$, $-CN$, $-OCF_3$, amino or mono- or dialkylamino
 n is 0, 1, 2 or 3;
 p and q are independently 0, 1, 2, 3 or 4;
 25 r is 1, 2 or 3; and
 s is 0, 1 or 2;
 with the proviso that said compound of formula (IB) is not a compound selected from:


- 1-(1-phenyl-3-pyrrolidinyl)-3-phenyl urea;
 1-(1-phenyl-3-pyrrolidinyl)-3-(4-methoxyphenyl)urea;
N-(4-Fluorophenyl)-*N'*-[*((R)*-1-((3-methylphenyl)pyrrolidin-2-ylmethyl))]urea;
N-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
 5 *N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
N-(4-Fluorophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
N-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-2-ylmethyl)]urea;
N-(4-Fluorophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
N-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
 10 *N*-(4-Fluorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
N-(4-Fluorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)]pyrrolidin-3-yl)]urea;
N-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
N-(1-Naphthyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
N-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
 15 *N*-(2-Bromophenyl)-*N'*-[*((S)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
N-(2-Bromophenyl)-*N'*-[*((R)*-1-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)]urea;
N-(2-Bromophenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
N-(2-Bromophenyl)-*N'*-[*((R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea;
N-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
 20 *N*-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
N-(2,5-Dichlorophenyl)-*N'*-[*((R)*-1-(3-methylphenyl)pyrrolidin-3-yl)]urea;
N-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
N-(2,5-Dichlorophenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
N-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3-fluorophenyl)pyrrolidin-3-yl)]urea;
 25 *N*-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
N-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
N-(2,5-Dichlorophenyl)-*N'*-[*((R)*-1-(3,4-difluorophenyl)pyrrolidin-3-yl)]urea;
N-(3-Chloro-2-methylphenyl)-*N'*-[*((R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea; and
 30 *N*-(2,3-Dichlorophenyl)-*N'*-[*((R)*-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)]urea.

6. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, which process comprises coupling a compound of formula (II):



(II)

in which R^1 , P and p are as defined in formula (I) with a compound of formula (III):



(III)

- in which P' , R^2 , n, q, r and s are as defined in formula (I) and A and B contain appropriate functional groups which are capable of reacting together to form the urea moiety;
- and thereafter, as necessary, carrying out one or more of the following reactions:
- (i) converting one compound of formula (I) into another compound of formula (I);
 - (ii) removing any protecting group;
 - (iii) preparing a salt or a solvate of the compound so formed.

7. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, for use as an active therapeutic substance.

8. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, for use in the treatment and/or prophylaxis of the Disorders of the Invention.
- 5 9. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, for use in the treatment and/or prophylaxis of pain.
- 10 10. A method for the treatment and/or prophylaxis of disorders in which antagonism of the Vanilloid (VR1) receptor is beneficial, in mammals including humans, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
- 15 11. A method according to claim 11, wherein said disorders are the Disorders of the Invention.
- 20 12. The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prophylaxis of disorders in which antagonism of the Vanilloid (VR1) receptor is beneficial.
- 25 13. A use according to claim 13 wherein said disorders are the Disorders of the Invention.
- 30 14. A pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, and a pharmaceutically acceptable carrier or excipient therefor.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number
WO 03/022809 A3

(51) International Patent Classification⁷: C07D 401/04,
401/14, 401/12, A61K 31/4025, 31/4709, 31/4725, A61P
25/00, 9/10

(74) Agent: GIDDINGS, Peter, John; GlaxoSmithKline,
Corporate Intellectual Property_CN925.1, 980 Great West
Road, Brentford, Middlesex TW8 9EP (GB).

(21) International Application Number: PCT/GB02/04206

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
13 September 2002 (13.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0122156.3 13 September 2001 (13.09.2001) GB
0130547.3 20 December 2001 (20.12.2001) GB
0130503.6 20 December 2001 (20.12.2001) GB
0130505.1 20 December 2001 (20.12.2001) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; 980
Great West Road, Brentford, Middlesex TW8 9GS (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): RAMI, Harshad,
Kantilal [GB/GB]; GlaxoSmithKline, New Frontiers Sci-
ence Park South, Third Avenue, Harlow, Essex CM19 5AW
(GB). THOMPSON, Mervyn [GB/GB]; GlaxoSmithK-
line, New Frontiers Science Park South, Third Avenue,
Harlow, Essex CM19 5AW (GB). WYMAN, Paul, Adrian
[GB/GB]; GlaxoSmithKline, New Frontiers Science Park
South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(88) Date of publication of the international search report:
17 July 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN



(57) Abstract: Certain compounds of formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R¹, R², P, P', n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition for the treatment of disorders relating to the vanilloid receptor (VR1) such as pain, migraine, neuropathy, ischaemia, neurodegeneration, stroke, multiple sclerosis, asthma, inflammatory diseases.

WO 03/022809 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/04206

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04 C07D401/14 C07D401/12 A61K31/4025 A61K31/4709
A61K31/4725 A61P25/00 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 424 760 A (WELSTEAD WILLIAM J JR ET AL) 28 January 1969 (1969-01-28) cited in the application column 1, line 45 - line 54 column 4; example 3 ---	1,2,5-9
X	US 3 424 761 A (LUNS福德 CARL D ET AL) 28 January 1969 (1969-01-28) cited in the application page 1, line 43 - line 51 column 5; example 8 ---	1,2,5-9
E	WO 02 090326 A (RAMI HARSHAD KANTILAL ; WYMAN PAUL ADRIAN (GB); THOMPSON MERVYN (GB) 14 November 2002 (2002-11-14) claims 1-10 --- -/--	1,2,5-9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

11 April 2003

Date of mailing of the international search report

27.05.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seitner, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/04206

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TANIGUCHI, NOBUAKI ET AL: "Preparation of heterocyclic moiety-containing benzonitrile derivatives as antiandrogen agents" retrieved from STN Database accession no. 136:279475 XP002225002 CAS RN: 405907-66-6; 405907-67-7 abstract -& JP 2002 088073 A (YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN) 27 March 2002 (2002-03-27) examples 6-1,6-2</p>	1,2,7
X	<p>PAN P-C ET AL: "Soluble Polymer-Supported Synthesis of Arylpiperazines" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 39, no. 51, 17 December 1998 (1998-12-17), pages 9505-9508, XP004144238 ISSN: 0040-4039 example 10C</p>	1,2
X	<p>HELSLEY G C ET AL: "SYNTHESIS AND BIOLOGICAL ACTIVITY OF SOME 1-SUBSTITUTED 3-PYRROLIDINYLUREAS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 11, no. 5, September 1968 (1968-09), pages 1034-1037, XP001095126 ISSN: 0022-2623 examples 38,40; table III</p>	1,2,7
A	<p>WO 01 28987 A (DU PONT PHARM CO) 26 April 2001 (2001-04-26) examples 15-22 claims 26,27</p>	1,7,8
A	<p>EP 0 790 240 A (TANABE SEIYAKU CO) 20 August 1997 (1997-08-20) example 114; table 13 example 105; table 11 page 79, line 16-22</p>	1,7,8
X	<p>US 4 001 422 A (DANILEWICZ JOHN C ET AL) 4 January 1977 (1977-01-04) abstract; examples 16,19</p>	1,7
-/--		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 02/04206

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MASTERS, JOHN J. ET AL: "Non-Amidine-Containing 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa with Potent Anticoagulant and Antithrombotic Activity" JOURNAL OF MEDICINAL CHEMISTRY (2000), 43(11), 2087-2092 , XP002238143 abstract examples 13,15,18,20,22-25	1,2,7
X	WO 99 00128 A (BEIGHT DOUGLAS WADE ;GOODSON THEODORE JUNIOR (US); HERRON DAVID KE) 7 January 1999 (1999-01-07) examples 40B,40C,40D	1,2
X	WO 99 00121 A (BEIGHT DOUGLAS WADE ;GOODSON THEODORE JR (US); HERRON DAVID KENT () 7 January 1999 (1999-01-07) abstract; examples 216,216B,216C,217-222	1,2,7
A	WO 92 19618 A (ABBOTT LAB) 12 November 1992 (1992-11-12) examples 14-16 page 5, line 17 - line 20	1,8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 02/04206

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10 and 11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,2,5-14 (all partially);

Compounds according to the general formula (I) of claim 1 in which P=aryl and P'=aryl as well as the method for their preparation and their therapeutical use.

2. Claims: 1-4,6-14 (all partially)

Compounds according to the general formula (I) of claim 1 in which P=aryl and P'=heteroaryl as well as the method for their preparation and their therapeutical use.

3. Claims: 1,2,5-14 (all partially)

Compounds according to the general formula (I) of claim 1 in which P=heteroaryl and P'=aryl as well as the method for their preparation and their therapeutical use.

4. Claims: 1-4,6-14 (all partially)

Compounds according to the general formula (I) of claim 1 in which P=heteroaryl and P'=heteroaryl as well as the method for their preparation and their therapeutical use.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/04206

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 3424760	A	28-01-1969	NONE	
US 3424761	A	28-01-1969	GB 1172033 A	26-11-1969
WO 02090326	A	14-11-2002	WO 02090326 A1	14-11-2002
JP 2002088073	A	27-03-2002	NONE	
WO 0128987	A	26-04-2001	AU 1201401 A EP 1220836 A2 WO 0128987 A1	30-04-2001 10-07-2002 26-04-2001
EP 0790240	A	20-08-1997	CA 2197364 A1 CN 1165815 A DE 790240 T1 EP 0790240 A1 ES 2106717 T1 GR 97300037 T1 JP 10195037 A SG 44166 A1 US 5849732 A	16-08-1997 26-11-1997 29-01-1998 20-08-1997 16-11-1997 28-11-1997 28-07-1998 14-11-1997 15-12-1998
US 4001422	A	04-01-1977	GB 1460389 A AR 216046 A1 AR 214049 A1 AR 213407 A1 AR 214050 A1 AR 207895 A1 AR 212447 A1 AR 215882 A1 AT 344184 B AT 453077 A AU 8317475 A BG 27086 A3 BG 27744 A3 BG 27745 A3 CA 1060445 A1 CH 611616 A5 CH 608803 A5 DD 119046 A5 DE 2530894 A1 DK 337175 A ,B, FI 752104 A ,B, FR 2279406 A1 HK 61879 A IE 41838 B1 IL 47625 A JP 1036278 C JP 51036469 A JP 55027062 B KE 2988 A LU 73072 A1 MY 10880 A NL 7508824 A ,B, PH 14190 A RO 69296 A1 RO 71841 A1 RO 71840 A1	06-01-1977 30-11-1979 30-04-1979 31-01-1979 30-04-1979 08-11-1976 14-07-1978 15-11-1979 10-07-1978 15-11-1977 20-01-1977 15-08-1979 12-12-1979 12-12-1979 14-08-1979 15-06-1979 31-01-1979 05-04-1976 05-02-1976 26-01-1976 26-01-1976 20-02-1976 07-09-1979 09-04-1980 30-01-1981 26-02-1981 27-03-1976 17-07-1980 28-09-1979 24-03-1977 31-12-1980 27-01-1976 26-03-1981 30-08-1981 15-08-1980 09-09-1982

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/04206

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4001422	A		SE	420921 B	09-11-1981
			SE	7508101 A	26-01-1976
			YU	124181 A1	30-04-1983
			YU	124281 A1	30-04-1983
			YU	184275 A1	27-04-1983
			AT	344185 B	10-07-1978
			AT	453177 A	15-11-1977
			AT	344186 B	10-07-1978
			AT	453277 A	15-11-1977
			AT	344178 B	10-07-1978
			AT	525275 A	15-11-1977
			BE	831654 A1	23-01-1975
			CS	192549 B2	31-08-1979
			CS	192534 B2	31-08-1979
WO 9900128	A	07-01-1999	AU	8270298 A	19-01-1999
			EP	1019045 A1	19-07-2000
			JP	2002508771 T	19-03-2002
			US	2002173518 A1	21-11-2002
			WO	9900128 A1	07-01-1999
			US	6372759 B1	16-04-2002
WO 9900121	A	07-01-1999	AU	8270898 A	19-01-1999
			EP	1014962 A1	05-07-2000
			JP	2002512633 T	23-04-2002
			WO	9900121 A1	07-01-1999
			US	6313122 B1	06-11-2001
			US	2002120007 A1	29-08-2002
WO 9219618	A	12-11-1992	US	5149704 A	22-09-1992
			IE	920801 A1	04-11-1992
			PT	100443 A	31-08-1993
			WO	9219618 A1	12-11-1992

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)